| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
153,922,000 |
| Market
Cap: |
6.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$37.79 - $39.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IVERIC bio is biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Co.'s clinical stage product candidate, Zimura® (avacincaptad pegol), a complement C5 inhibitor. Co. is targeting the following diseases with Zimura: Geographic Atrophy, intermediate age-related macular degeneration, and autosomal recessive Stargardt disease. In addition to Zimura, Co. is developing its preclinical product candidate IC-500, a high temperature requirement A serine peptidase 1 protein inhibitor, for GA and potentially other age-related retinal diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
40,000 |
561,286 |
| Total Sell Value |
$0 |
$0 |
$1,546,400 |
$15,378,126 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
2 |
30 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Peacock Bruce |
CFO & CBO |
• – – |
2014-03-24 |
4 |
OE |
$1.65 |
$10,228 |
D/D |
6,191 |
6,191 |
|
- |
|
| Sv Life Sciences Fund Iv Strategic Partners, L. P. |
10% Owner |
– – • |
2014-02-18 |
4 |
S |
$29.61 |
$20,839,163 |
D/D |
(703,788) |
140,228 |
|
- |
|
| Sv Life Sciences Fund Iv Strategic Partners, L. P. |
10% Owner |
– – • |
2014-02-18 |
4 |
S |
$29.61 |
$41,678,325 |
I/I |
(1,407,576) |
5,079,458 |
|
- |
|
| Sblendorio Glenn |
Director |
– • – |
2013-09-30 |
4 |
AB |
$22.00 |
$22,000 |
D/D |
1,000 |
1,000 |
|
- |
|
| Galakatos Nicholas |
Director |
– • • |
2013-09-30 |
4 |
B |
$22.00 |
$55,000 |
I/I |
2,500 |
2,500 |
2.25 |
- |
|
| Galakatos Nicholas |
Director |
– • • |
2013-09-30 |
4 |
B |
$22.00 |
$55,000 |
D/D |
2,500 |
2,500 |
3.92 |
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2013-09-30 |
4 |
B |
$22.00 |
$5,016,000 |
D/D |
228,000 |
3,639,902 |
2.45 |
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,411,901 |
3,411,902 |
|
- |
|
| Steinmetz Michael |
10% Owner |
– – • |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,728,400 |
2,728,390 |
|
- |
|
| Novo A/s |
SEE REMARKS |
– – • |
2013-09-30 |
4 |
B |
$22.00 |
$10,010,000 |
D/D |
455,000 |
6,896,819 |
2.45 |
- |
|
| Novo A/s |
SEE REMARKS |
– – • |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
6,441,819 |
6,441,819 |
|
- |
|
| Dyrberg Thomas |
Director |
– • – |
2013-09-30 |
4 |
B |
$22.00 |
$15,400 |
D/D |
700 |
700 |
2.39 |
- |
|
| Patel Samir Chandrakant |
President |
• • – |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
384,981 |
537,527 |
|
- |
|
| Sv Life Sciences Fund Iv (gp), L.p. |
10% Owner |
– – • |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,783,244 |
159,657 |
|
- |
|
| Sv Life Sciences Fund Iv (gp), L.p. |
10% Owner |
– – • |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
11,566,488 |
5,783,244 |
|
- |
|
| Bolte Axel |
Director |
– • – |
2013-09-25 |
4 |
S |
$22.00 |
$44,000 |
D/D |
(2,000) |
2,000 |
|
- |
|
| Patel Samir Chandrakant |
PresidentOfficer |
• • – |
2013-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
152,543 |
|
- |
|
| Guyer David R |
Chief Executive OfficerOfficer |
• • – |
2013-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,610 |
|
- |
|
| Patel Samir Chandrakant |
President |
• • – |
2013-09-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,168 |
152,543 |
|
- |
|
494 Records found
|
|
Page 20 of 20 |
|
|
